PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
34.57%
Cash & equivalents growing 34.57% while TRAW's declined -24.75%. Peter Lynch would see this as a sign of superior liquidity management.
68.63%
Higher Short-Term Investments Growth compared to TRAW's zero value, indicating better performance.
34.59%
Below half of TRAW's -24.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.58%
Below half of TRAW's -24.56%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-15.03%
Similar yoy growth to TRAW's -13.79%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.19%
0.75-0.9x TRAW's -13.33%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Below half of TRAW's -24.45%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-18.99%
Less than half of TRAW's 8.50%. David Dodd sees a more disciplined AP approach or lower volume.
-51.38%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-91.88%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-10.37%
Exceeding 1.5x TRAW's -1.42%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-15.50%
Above 1.5x TRAW's -7.70%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.50%
Above 1.5x TRAW's -3.91%. Michael Burry sees a potential leverage warning sign.
13.39%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-7.92%
≥ 1.5x TRAW's -2.92%. David Dodd sees higher yoy retained profits than competitor.
-32.48%
Less than half of TRAW's 67.44%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
41.56%
Below half TRAW's -68.15%. Michael Burry sees potential underperformance in building shareholder capital.
31.29%
Below half TRAW's -24.45%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
68.63%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-51.38%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-35.43%
Less than half of TRAW's 24.75%. David Dodd sees better deleveraging or stronger cash buildup than competitor.